Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy

Weigand, Isabel; Altieri, Barbara; Lacombe, Amanda; Basile, Vittoria ; Kircher, Stefan; Landwehr, Laura-Sophie; Schreiner, Jochen; Zerbini, Maria; Ronchi, Cristina; Megerle, Felix; Berruti, Alfredo; Canu, Letizia; Volante, Marco; Paiva, Isabel; Della Casa, Silvia; Sbiera, Silviu; Fassnacht, Martin; Fragoso, Maria ; Terzolo, Massimo; Kroiss, Matthias

DOI:
10.1210/clinem/dgaa293

Document Version
Peer reviewed version

Citation for published version (Harvard):
Weigand, I, Altieri, B, Lacombe, A, Basile, V, Kircher, S, Landwehr, L-S, Schreiner, J, Zerbini, M, Ronchi, C, Megerle, F, Berruti, A, Canu, L, Volante, M, Paiva, I, Della Casa, S, Sbiera, S, Fassnacht, M, Fragoso, M, Terzolo, M & Kroiss, M 2020, 'Expression of SOAT1 in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study', *The Journal of clinical endocrinology and metabolism*, vol. 105, no. 8. https://doi.org/10.1210/clinem/dgaa293

Expression of sterol-O-acyl transferase 1 (SOAT1) in adrenocortical carcinoma and response to mitotane monotherapy: an ENSAT multicenter study

Isabel Weigand[1], Barbara Altieri[1], Amanda M. F. Lacombe[2], Vittoria Basile[3], Stefan Kircher[4], Laura-Sophie Landwehr[1], Jochen Schreiner[1], Maria C. N. Zerbini[2], Cristina L. Ronchi[1,5,6], Felix Megerle[1], Alfredo Berruti[7], Letizia Canu[8], Marco Volante[9], Isabel Paiva[10], Silvia Della Casa[11], Silviu Sbiera[1], Martin Fassnacht[1,12], Maria Candida B. V. Fragoso[2], Massimo Terzolo[3], Matthias Kroiss[1,12]

[1]Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany

[2] Unidade de Suprarrenal, Laboratorio de Hormônios e Genetica Molecular LIM42, Serviço de Endocrinologi e Metaboligia, Hospital de Clínicas; Departamento de Patologia, Faculdade de Medicina da Universidade de São Paulo, Brazil, Instituto do Câncer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo, São Paul, Brazil

[3]Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Turin, Italy

[4]Institute of Pathology, University of Würzburg, Würzburg, Germany

[5]Institute of Metabolism and System Research, University of Birmingham, Birmingham, UK

[6]Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners Birmingham, UK

[7]Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia at ASST Spedali Civili, Brescia, Italy

[8]Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

[9]Department of Oncology, University of Turin, Turin, Italy

[10] University Hospital of Coimbra, Coimbra, Portugal

[11] Division of Endocrinology and Metabolism, Fondazione Policlinico Gemelli, Catholic University, Rome, Italy

[12]Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany

Short title: SOAT1 expression and mitotane

Key words: adrenal cancer, chemotherapy, treatment, prognosis

Correspondence and request for reprints to:
Matthias Kroiss, MD, PhD

Division of Endocrinology and Diabetology,

University Hospital of Würzburg,

Oberdürrbacher Str. 6

97080 Würzburg (Germany)

Telephone: +49-931-201-39740

Email: Kroiss_m@ukw.de

Disclosure:
The authors have nothing to disclose.

Financial support:
This work has been supported by grants from the DFG German Research Foundation (grant KR-4371/1-2 to M.K, FA-466/4-2 to M.F. and RO-5435-3-3 to C.L.R.), the DFG German Research Foundation Project 314061271- TRR 205 (M.F. & M.K.) from Fundação de Amparo à Pesquisa do Estado de São Paulo (grant 2017/26345-5 to M.C.B.V.F.), Else Kröner-Fresenius-Stiftung (Grant 2016_A96 to S.S. and M.K) and from Deutsche Krebshilfe (grant 70112969 to C.L.R. & M. F.).

Precis (max 200 Zeichen)

Mitotane is a cornerstone of adrenal cancer treatment. In this international study, expression of putative mitotane target SOAT1 in tissue did not predict treatment response to mitotane monotherapy.

Abstract (max 250 words)

Context Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20% and adverse drug effects are frequent. To date there is no marker established that predicts treatment response. Mitotane has been shown to inhibit sterol-O-acyl transferase 1 (SOAT1) which leads to endoplasmic reticulum stress and cell death in ACC cells.

Objective To investigate SOAT1 protein expression as a marker of treatment response to mitotane.

Patients 231 ACC patients treated with single agent mitotane as adjuvant (n=158) or advanced disease therapy (n=73) from twelve ENSAT centers were included. SOAT1 protein expression was determined by immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) specimens.

Main outcome measure: recurrence-free survival (RFS), progression-free survival (PFS), disease-specific survival (DSS)

Results 61/135 patients (45 %) with adjuvant mitotane treatment had recurrences and 45/68 patients (66 %) with mitotane treatment for advanced disease had progressive disease. After multivariate adjustment for sex, age, hormone secretion, tumour stage and Ki67 index, RFS (HR=1.07, 95% CI 0.61-1.85, p=0.82) and DSS (HR=1.30, 95% CI 0.58-2.93, p=0.53) in adjuvantly treated ACC patients did not differ significantly between tumors with high and low SOAT1 expression. Similarly, in the advanced stage setting, PFS (HR=1.34, 95% CI 0.63-2.84, p=0.45) and DSS (HR=0.72, 95% CI 0.31-1.70, p=0.45) were comparable and response rates not significantly different.

Conclusions SOAT1 expression was not correlated with clinical endpoints RFS, PFS and DSS in ACC patients with mitotane monotherapy. Other factors appear to be relevant for mitotane treatment response and ACC patient survival.

Introduction

Adrenocortical carcinoma (ACC) is a rare malignancy with a generally poor prognosis [1] and limited effective treatment options [1, 2]. Mitotane is the only approved drug for metastatic disease [3] but efficacy is very limited and the observed objective response rate is only approximately 20 % [4-6]. Controversy exists regarding adjuvant use which is supported by a large retrospective study [6, 7] and advocated by current guidelines [2] in patients at moderate or high risk of recurrence after complete resection. Adverse drug effects like adrenal insufficiency, diarrhea, nausea and other gastrointestinal symptoms but also central nervous symptoms such as dizziness and speech disturbance may be severe and disabling [8-10] and must be balanced against potential treatment benefits. Mitotane efficacy is correlated with plasma concentrations above 14 mg/l [11]. Therapeutic drug monitoring (TDM) is therefore recommended [2]. Some patients for unknown reasons fail to achieve mitotane plasma concentrations within the therapeutic window which is associated with decreased efficacy [5, 12]. To date, few markers have been suggested for the prediction of response [13, 14], but they have not been validated in a large series. Establishment of such a marker would be a major advancement in ACC treatment and enable tailored treatment of potential responders and avoidance of unnecessary mitotane exposure in non-responders.

We have provided evidence that mitotane inhibits sterol-O-acyl transferase 1 (SOAT1) also known as ACAT1 [15] (not to be mistaken with acetyl-CoA acetyltransferase known under the same name), an enzyme catalyzing the esterification of cholesterol in the adrenal cortex [16]. This leads to the accumulation of toxic lipids and endoplasmic reticulum (ER) stress which results in apoptosis of adrenocortical cells [15]. Accordingly, a SOAT1 inhibitor has been tested in a phase I clinical trial as a treatment for advanced ACC [17].

SOAT1 is strongly expressed in adrenocortical cell lines, normal adrenal glands and different adrenocortical tumor entities, with the highest variation among ACC, while it is only weakly to moderately expressed in non-adrenal tissues [15]. Despite strong evidence of an inhibitory effect on SOAT1, other mechanisms such as impaired mitochondrial respiration and function [18-20] may contribute to the relatively tissue-specific toxicity of mitotane.

In a small cohort of patients with advanced ACC, it has been shown that SOAT1 expression was correlated with the response to mitotane treatment [15].

Here, we aimed to validate in a large multicenter study whether SOAT1 expression is a predictive marker for mitotane efficacy by investigating the association of SOAT1 tissue expression with recurrence free survival (RFS) in patients with adjuvant mitotane treatment, progression-free survival (PFS) after mitotane monotherapy administered to patients with advanced disease and disease-specific survival (DSS) for both cases.

Patients and Methods

Setting and data acquisition

Formalin-fixed paraffin-embedded (FFPE) tumor specimens of 231 ACC were included from 12 centers belonging to the European Network for the Study of Adrenocortical Tumors (ENSAT; www.ensat.org). Only adult patients with histologically confirmed ACC were included [21]. Patients that have been included in our previous analyses of SOAT1 expression [15] have been excluded from this analysis. All patients started mitotane treatment as first medical therapy no later than 3 months after complete resection in the adjuvant setting (n=158) or diagnosis of irresectable or recurrent or metastatic ACC in the advanced stage setting (n=73). The study was conducted as part of the ENSAT registry, has been approved by the ethics committee at each participating institution and was conducted in accordance with the principles of the Declaration of Helsinki. All patients gave informed written consent.

Clinical and pathological data, including sex, age at diagnosis, date of diagnosis, tumor stage according to the ENSAT staging system [22], hormone secretion, Weiss score [21], Ki67 proliferation index, mitotane plasma concentrations after three and six months and response to treatment during follow-up were either provided by the participant center or collected through the ENSAT registry (https://registry.ensat.org).

Chromogenic immunohistochemistry

Full FFPE sections mounted on slides were deparaffinised, rehydrated and antigen retrieval was performed in 10mM citric acid monohydrate buffer (pH 6.5) under pressure for 13 min. Blocking of unspecific binding sites occurred with 20% human AB serum at room temperature (RT) for 1 h and the primary antibody (SOAT1; ab39327 Abcam) was incubated in a 1:1000 dilution for 1h at RT as previously described [15]. The N-Universal negative control anti-rabbit (Dako) was used and signal amplification was achieved by the Advance HRP Link Kit for 40 min and developed for 10 min with the DAB+ Liquid Kit (Dako). Nuclei

were counterstained using Mayer's hematoxylin for 3 min and blued for 5 min in running tap water. To ensure specificity of the antibody used [23], we overexpressed human SOAT1 in ACC cells which resulted in an increase of both detected SOAT1 bands and SOAT1 WB of 5 normal adrenal glands also resulted only in the two specific bands (Fig. S1).

Semi-quantitative analysis of SOAT1 immunoreactivity

Chromogenic staining intensities were determined by two independent investigators (I.W. and B.A. or L.-S.L.) and graded as 0 (negative), 1 (low), 2 (medium) and 3 (high). The proportion of positive tumor cells was calculated for each slide and scored 0 if 0% were positive, 0.1 if 1-9% were positive, 0.5 if 10-49% were positive and 1 if ≥50% were positive [24, 25]. A semi quantitative H-Score was then calculated by multiplying the staining intensity grading score with the proportion score. Where discrepancies were observed, results were jointly assessed by both investigators and the final score was formed by consensus. The Spearman's correlation for inter-observer agreement for each staining was high ($r>0.85$).

Statistical analysis

RFS and PFS were considered as the time between diagnosis and documented recurrence and progression (based on cross sectional imaging), respectively. DSS was calculated from the time of diagnosis until disease-related death or censored at last follow-up. RFS, PFS and DSS were analysed using the Kaplan–Meier method and groups were compared by using the log-rank test. Assessment of prognostic factors (ENSAT stage, ki67, age, sex, hormone secretion and for the group with advanced disease additionally: preM-TTP (pre mitotane time to progression= time between diagnosis and progress before initiation of mitotane treatment) was performed with the Cox proportional hazard regression model. The Chi-square test was used to investigate dichotomic variables, whereas non-parametric Kruskal-Wallis s test was used for comparison among groups for non-normal distributed variables. Correlations between H-Score and prognostic factors were evaluated by Spearman's correlation. P values <0.05 were considered statistically significant. Statistical analyses were performed with IBM SPSS Version 23 and GraphPad Prism Version 6.

Results

Patient characteristics

Clinical characteristics of 231 ACC patients are summarised in Table 1. Median age at diagnosis was 54.2 years (range 17-83) in the adjuvant group and 51 years (range 16-80) in the group with disease. In both groups, approximately 60% of the patients were female and 40% were male. At diagnosis, the majority of patients treated with mitotane monotherapy in the adjuvant setting had an ENSAT tumor stage of I-II (62.3%), whereas, in the advanced stage setting, most of the patients had a tumor stage of IV (55.6%). The remaining patients with advanced disease had a localized tumor at diagnosis and started mitotane therapy only

after developing local recurrence or metastases. Data regarding Ki67 index were available in 91.2% and 83.5% of patients in the adjuvant and advanced stage setting, respectively. 31 patients (21%) of the adjuvant group and 18 patients (27.3%) of the advanced stage group had Ki67 index staining below 10% (*p=0.35*, chi-square=0.88). Median Weiss score was 6 (range 1-9) in both groups. In both arms, about 70% of the tumors were hormonally active. Median time to start mitotane were one month in the adjuvant group and less than one month in the group with advanced disease. Median mitotane plasma levels at three months of therapy were 9.3 mg/l and 10 mg/l, after six months 13.5 mg/l and 12.8 mg/l in the adjuvant and advanced stage cohort, respectively. In the advanced stage group, preM-TTP was <365 days in 51/63 patients (81%) for DSS and <365 days in 52/67 patients (78%) for PFS.

No recurrence was observed in 74/135 patients within a median follow-up of 18.5 months (range 1-216 months) in patients treated in adjuvant setting. Best response to advanced stage mitotane was complete (n=1) or partial response in 9, stable disease in 13 and progressive disease in 45 patients. Median follow up of patients still alive (n=18) was 19.5 months (range 2-180 months) in this setting.

SOAT1 expression and correlation with known prognostic factors of ACC

Tissue SOAT1 expression differed widely in tumors of both the adjuvant and the group with advanced disease and exhibited different intra-tumoral patterns between homogeneous and heterogeneous staining intensity (Fig. 1). Semiquantitative H-score accounts for this heterogeneity as it takes into account both the staining intensity and percentage of cells being stained and ranged from 0 to 3. Scores from 0 to <2 were designated low expression (Fig. 1J-L) while scores ≥2 were indicative of high expression (Fig. 1A-I). No difference in SOAT1 expression was found between hormone producing and endocrine inactive ACC with mean staining intensities of 1.53 ±0.9 in inactive *vs.* 1.48 ±0.9 in hormonally active ACC, p=0.76. No correlation of SOAT1 H-score was observed with Ki67, ENSAT stage, Weiss score and age at diagnosis neither in the adjuvant, nor in the advanced stage setting.

SOAT1 expression as factor of survival and response to mitotane treatment in ACC

In the adjuvant setting (Fig. 2A), we did not observe significant differences of RFS between ACC patients with low SOAT1 expression in comparison to those with high SOAT1 expression (median 22 months, range 1-153 vs. median 12 months, range 1.5-216 log rank p=0.12). When we only included patients with Ki67≥10% to analyse RFS, we did not observe significant differences between SOAT1 low and high expressing ACC either (log rank p=0.73). DSS (Fig. 2B) did not significantly differ between patients whose tumors expressed low levels of SOAT1 compared to those with high SOAT1 expression (median 51 months, range 1-252 *vs.* 31 months, range 2-216 log rank p=0.23). Similarly, in the group with advanced disease, no significant difference in PFS (Fig. 2C) between patients with low

222 SOAT1 expression and those with high SOAT1 expression (median PFS 5 months, range 1-
223 59 vs. median 4 months, range 1-25 log rank p= 0.66) was observed. Median DSS (Fig. 2D)
224 was likewise not different in tumors with low vs. high SOAT1 (median 22 months, range 4-
225 180 vs. 21 months, 2-83 months, log rank p=0.47). When we analysed all patients together
226 (Fig. S2A), low SOAT1 expression was associated with a significantly longer median
227 recurrence-/progression-free survival of 13 months (range 1 -153 months vs 8 months (range
228 1-216 months, log rank p=0.049). We did not observe a significant difference in DSS (Fig.
229 S2B) between tumors with low SOAT1 vs high SOAT1 expression (median: 41 months,
230 range 1 -252 vs. median: 28 months, range 2-216, log rank p=0.41).

231 The proportion of tumors with low and high SOAT1 expression did not differ between patients
232 in the adjuvant cohort without recurrence (low, n=44; high, n=30) and with recurrence (low,
233 n=35; high, n=26) (Fig. 3A). Similarly, in the cohort with advanced disease, there were no
234 differences between tumors with low and high SOAT1 regarding objective response to
235 mitotane (low, n=6; high, n=4) *vs.* stable disease (low, n=6; high, n=7) and progressive
236 disease (low, n=25; high, n=20), respectively (Fig. 3B).

237 We next aimed at multivariable adjustment for known clinical/histopathological ACC
238 prognostic factors. In the adjuvant arm, univariate analysis revealed only a Ki67-Index <10%
239 as significantly associated with improved DSS and RFS (Table 2). In patients with advanced
240 disease the following factors were significantly associated with improved DSS: male sex,
241 Ki67-Index <10% and preM-TTP >365 days. After multivariate analysis of all factors,
242 including SOAT1 expression, only preM-TTP >365 days retained statistical significance
243 (Table 3).

244 **SOAT1 expression is not related to mitotane plasma concentrations**

245 We next examined the potential association of SOAT1 expression with mitotane plasma
246 concentrations. Mitotane plasma levels after three months of treatment did not significantly
247 differ between patients whose tumors showed high vs low expression of SOAT1 both in the
248 adjuvant (median mitotane levels:10.3 mg/l *vs* 9.1 mg/l) and in the advanced disease setting
249 (median mitotane levels: 11.7 mg/l *vs* 9.1 mg/l) (Fig. 4A). SOAT1 expression was not
250 associated with mitotane plasma concentrations above 14 mg/l neither in the adjuvant (Fig.
251 4B) nor in the advanced disease arm (Fig. 4C). Similar results were observed after six
252 months of mitotane treatment (median mitotane levels 14.2 mg/l *vs* 13 mg/l in the adjuvant
253 group and 11.9 mg/l *vs* 12.8 mg/l in the group with advanced disease). When analyzing only
254 patients reaching the mitotane target level of 14 mg/l after three months, significantly fewer
255 patients with high SOAT1 expression responded to therapy (Fig. 4D) while this difference
256 was no longer observed when considering the six months time point (Fig. 4E).

257 Median dose of mitotane intake was 4 g/daily (range 1-12 g) in the adjuvant arm and 5
258 g/daily (range 2-12 g/daily) in patients treated for advanced disease and did not significantly
259 differ between the SOAT1 high and low expressing group (*p= 0.6* (adjuvant) and *p=0.4*
260 (advanced disease)).

261 **Discussion**

262 Mitotane is the only approved drug for the treatment of ACC, however, objective response
263 rates are only approximately 20% [5, 6]. In addition to its limited therapeutic potential,
264 adverse events occur frequently and reliable markers predicting response to therapy are
265 currently not established. Therefore, it is crucial to define a particular subgroup of patients
266 that will take advantage from treatment and to avoid toxicity in patients unlikely to respond.

267 At present, this topic has been addressed only in a limited number of patients [13, 14] and
268 very recently a study demonstrated mitotane sensitivity only in a very specific sub-group of
269 patients [26]. Although mitotane has been used in the clinic for decades, its precise
270 mechanism of action and molecular target remained unknown for decades, despite intense
271 research including several different “omics” approaches [18-20, 27]. We demonstrated that
272 mitotane inhibits SOAT1, leading to ER-stress and cell death of adrenocortical cells [15]. It
273 was also shown that SOAT1 is predominantly expressed in adrenocortical cells, compared to
274 cells of non-adrenal origin [15], possibly explaining the specific adrenolytic toxicity of
275 mitotane. In addition, in glioblastoma, inhibition of SOAT1 has been proposed as a novel
276 treatment [28, 29].

277 In hepatocellular carcinoma high SOAT1 expression was associated with a worse prognosis
278 [30] and has previously been described in prostate cancer as well [31]. An adverse outcome
279 of SOAT1 expression in ACC was recently demonstrated [32]. These results suggest that the
280 elevated expression of SOAT1 could be a prognostic feature of diverse cancers. In a small
281 single center series of patients (n=25) with advanced ACC [15], we had previously shown
282 that SOAT1 expression is associated with improved progression-free survival. This ENSAT
283 multicenter retrospective study aimed at validating the value of SOAT1 as a histologic marker
284 for mitotane response. Our results disprove our initial hypothesis, as no significant
285 differences in response to mitotane treatment could be observed between ACC tissue
286 samples with high and low levels of SOAT1 protein neither in an adjuvant setting nor in
287 patients treated with advanced disease.

288 Our study has the strength of a large collection of tissue samples from specialized ACC
289 centers. SOAT1 expression was histologically determined in a centralized manner. All
290 patients received mitotane monotherapy, no additional therapies were used during mitotane
291 treatment. However, our study has several limitations. First, the clinical data and samples

collection were retrospectively retrieved from twelve different ENSAT centers (11 European and one from Brazil) which likely is associated with different treatment strategies. This not only comprises surgery and medical treatment but also documentation and follow-up. Second, mitotane treatment itself is cumbersome and different dosing regimens are in use at different centers [33-35]. In addition, patient-specific factors that are only partially understood lead to a high heterogeneity of mitotane plasma concentrations [36-38]. Accordingly, mitotane plasma concentrations in our cohort after three and six months of treatment were highly variable. When considering only patients who reached mitotane plasma concentrations of >14 mg/L at three or six months, SOAT1 expression was not correlated to clinical response.

The lack of an association of SOAT1 expression with survival endpoints and response implicates that additional target molecules different from SOAT1 may be relevant for its toxic effect in adrenal cortical cells. *In vitro*, SOAT1 expression was shown to not be a predictor as demonstrated in few ACC primary cultures [23] which would support the theory that additional targets might be of greater importance. One such potential mechanism includes inhibition of mitochondrial respiratory chain. The novel compound nevanimibe (previously known as ATR101) which has been developed as a new treatment for ACC has been shown to be a potent SOAT1 inhibitor by one group [39] but was also shown to inhibit mitochondrial respiration by a different group [40] similar to mitotane.

Importantly, we found pronounced heterogeneity of SOAT1 expression in approximately 20 % of tumor samples. It is conceivable that this tissue heterogeneity was not completely accounted for in the monocentric study by Ferreira Lacombe *et al.* [32] in which a tissue microarrays were used to evaluate SOAT1 expression whereas we used full sections. Relationship of SOAT1 with Ki67 index and cortisol secretion was demonstrated in the previous study but not in ours. However, in our study ki67 value was provided by the various participating centers and thus a uniform analysis of this index is not guaranteed.

In an adjuvant setting, several other known factors such as resection status or Ki67 index [41], are important to predict tumor recurrence, since even after complete resection, recurrence rates are high [42-44]. In line with previous studies, Ki67-index below 10% (Table 2) was significantly associated with a better DSS and TTP in our cohort of patients treated with mitotane in this setting. Similarly, in advanced ACC, Ki67 index, mutational burden [45] but also clinical factors like age or presence of symptoms, have been identified [46, 47] to predict patient outcome independently of mitotane treatment [48]. In our cohort of patients with advanced disease, mitotane monotherapy, Ki67-Index below 10% was also associated with a better DSS (Table 3), which retained significance after multivariate adjustment but was not observed for TTP in a univariate analysis (Table 3). This may be due to the relatively

328 small cohort but is in line with a previous study in which only the DSS, but not the TTP
329 correlated with a Ki67-Index below 10% in advanced ACC [5].

330 In conclusion, in this multicenter study, we could not confirm SOAT1 expression to be a
331 clinically useful marker to predict treatment response to mitotane.

332

333 **Contributors:**
334 The following scientists contributed tissue samples and clinical data in addition to those listed
335 as co-authors:

336 Marcus Quinkler (Berlin), Masanori Murakami (Munich), Felix Beuschlein (Munich, Zurich),
337 Harm R. Haak (Eindhoven), Marcin Motyka (Krakow), Vasileois Chortis (Birmingham) and
338 Annamaria Colao (Naples).

339 **Acknowledgment**
340 We are grateful to Michaela Haaf and Martina Zink for sample and data administration and
341 Kerstin Lenz for expert technical assistance.

342

343 **References**

344 1. Fassnacht, M., M. Kroiss, and B. Allolio, *Update in adrenocortical carcinoma.* J Clin Endocrinol
345 Metab, 2013. **98**(12): p. 4551-64.
346 2. Fassnacht, M., et al., *European Society of Endocrinology Clinical Practice Guidelines on the*
347 *Management of Adrenocortical Carcinoma in Adults, in collaboration with the European*
348 *Network for the Study of Adrenal Tumors.* Eur J Endocrinol, 2018.
349 3. Schteingart, D.E., et al., *Management of patients with adrenal cancer: recommendations of*
350 *an international consensus conference.* Endocr Relat Cancer, 2005. **12**(3): p. 667-80.
351 4. Reidy-Lagunes, D.L., et al., *Complete Responses to Mitotane in Metastatic Adrenocortical*
352 *Carcinoma-A New Look at an Old Drug.* Oncologist, 2017. **22**(9): p. 1102-1106.
353 5. Megerle, F., et al., *Mitotane Monotherapy in Patients With Advanced Adrenocortical*
354 *Carcinoma.* J Clin Endocrinol Metab, 2018. **103**(4): p. 1686-1695.
355 6. Terzolo, M., et al., *Adjuvant mitotane treatment for adrenocortical carcinoma.* N Engl J Med,
356 2007. **356**(23): p. 2372-80.
357 7. Berruti, A., et al., *Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With*
358 *Radically Resected Adrenocortical Carcinoma.* J Clin Endocrinol Metab, 2017. **102**(4): p. 1358-
359 1365.
360 8. Fassnacht, M. and B. Allolio, *Clinical management of adrenocortical carcinoma.* Best Pract
361 Res Clin Endocrinol Metab, 2009. **23**(2): p. 273-89.
362 9. Else, T., et al., *Adrenocortical carcinoma.* Endocr Rev, 2014. **35**(2): p. 282-326.
363 10. Daffara, F., et al., *Prospective evaluation of mitotane toxicity in adrenocortical cancer*
364 *patients treated adjuvantly.* Endocr Relat Cancer, 2008. **15**(4): p. 1043-53.
365 11. Hermsen, I.G., et al., *Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors*
366 *of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T*
367 *multicenter study.* J Clin Endocrinol Metab, 2011. **96**(6): p. 1844-51.
368 12. Terzolo, M., et al., *Mitotane levels predict the outcome of patients with adrenocortical*
369 *carcinoma treated adjuvantly following radical resection.* Eur J Endocrinol, 2013. **169**(3): p.
370 263-70.
371 13. Ronchi, C.L., et al., *CYP2W1 is highly expressed in adrenal glands and is positively associated*
372 *with the response to mitotane in adrenocortical carcinoma.* PLoS One, 2014. **9**(8): p. e105855.
373 14. Volante, M., et al., *Ribonucleotide reductase large subunit (RRM1) gene expression may*
374 *predict efficacy of adjuvant mitotane in adrenocortical cancer.* Clin Cancer Res, 2012. **18**(12):
375 p. 3452-61.
376 15. Sbiera, S., et al., *Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated*
377 *Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.*
378 Endocrinology, 2015. **156**(11): p. 3895-908.
379 16. Lee, H.T., et al., *Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as*
380 *hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of*
381 *sulfonamides, acylphosphonamides and acylphosphoramidates.* Bioorg Med Chem Lett, 1998.
382 **8**(3): p. 289-94.
383 17. Smith, D.C., et al., *A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-*
384 *acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma.* Invest New Drugs, 2020.
385 18. Hescot, S., et al., *Mitotane alters mitochondrial respiratory chain activity by inducing*
386 *cytochrome c oxidase defect in human adrenocortical cells.* Endocr Relat Cancer, 2013. **20**(3):
387 p. 371-81.
388 19. Poli, G., et al., *Morphofunctional effects of mitotane on mitochondria in human*
389 *adrenocortical cancer cells.* Endocrine-Related Cancer, 2013. **20**(4): p. 537-550.
390 20. Hescot, S., et al., *Identifying mitotane-induced mitochondria-associated membranes*
391 *dysfunctions: metabolomic and lipidomic approaches.* Oncotarget, 2017. **8**(66): p. 109924-
392 109940.
393 21. Weiss, L.M., L.J. Medeiros, and A.L. Vickery, Jr., *Pathologic features of prognostic significance*
394 *in adrenocortical carcinoma.* Am J Surg Pathol, 1989. **13**(3): p. 202-6.

395 22. Fassnacht, M., et al., *Limited prognostic value of the 2004 International Union Against Cancer*
396 *staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.*
397 Cancer, 2009. **115**(2): p. 243-50.
398 23. van Koetsveld, P.M., et al., *The Efficacy of Mitotane in Human Primary Adrenocortical*
399 *Carcinoma Cultures.* J Clin Endocrinol Metab, 2019.
400 24. Olaussen, K.A., et al., *DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based*
401 *adjuvant chemotherapy.* N Engl J Med, 2006. **355**(10): p. 983-91.
402 25. Weigand, I., et al., *Differential expression of the protein kinase A subunits in normal adrenal*
403 *glands and adrenocortical adenomas.* Sci Rep, 2017. **7**(1): p. 49.
404 26. Altieri, B., et al., *Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide*
405 *Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT*
406 *Study.* Cancers (Basel), 2020. **12**(2).
407 27. Zsippai, A., et al., *Effects of mitotane on gene expression in the adrenocortical cell line NCI-*
408 *H295R: a microarray study.* Pharmacogenomics, 2012. **13**(12): p. 1351-61.
409 28. Geng, F., et al., *Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1-*
410 *Mediated Lipogenesis.* Clin Cancer Res, 2016. **22**(21): p. 5337-5348.
411 29. Geng, F. and D. Guo, *Lipid droplets, potential biomarker and metabolic target in*
412 *glioblastoma.* Intern Med Rev (Wash D C), 2017. **3**(5).
413 30. Jiang, Y., et al., *Proteomics identifies new therapeutic targets of early-stage hepatocellular*
414 *carcinoma.* Nature, 2019. **567**(7747): p. 257-261.
415 31. Stopsack, K.H., et al., *Cholesterol uptake and regulation in high-grade and lethal prostate*
416 *cancers.* Carcinogenesis, 2017. **38**(8): p. 806-811.
417 32. Lacombe, A.M.F., et al., *Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical*
418 *Carcinoma.* Cancers (Basel), 2020. **12**(1).
419 33. Kerkhofs, T.M., et al., *Comparison of two mitotane starting dose regimens in patients with*
420 *advanced adrenocortical carcinoma.* J Clin Endocrinol Metab, 2013. **98**(12): p. 4759-67.
421 34. Mauclere-Denost, S., et al., *High-dose mitotane strategy in adrenocortical carcinoma:*
422 *prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.*
423 Eur J Endocrinol, 2012. **166**(2): p. 261-8.
424 35. Baudin, E., et al., *Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD)*
425 *levels on the treatment of patients with adrenocortical carcinoma.* Cancer, 2001. **92**(6): p.
426 1385-92.
427 36. Kerkhofs, T.M., et al., *Development of a pharmacokinetic model of mitotane: toward*
428 *personalized dosing in adrenocortical carcinoma.* Ther Drug Monit, 2015. **37**(1): p. 58-65.
429 37. Arshad, U., et al., *Enzyme autoinduction by mitotane supported by population*
430 *pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.* Eur J
431 Endocrinol, 2018. **179**(5): p. 287-297.
432 38. Puglisi, S., et al., *Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical*
433 *Carcinoma Patients on Adjuvant Treatment.* J Clin Med, 2019. **8**(11).
434 39. LaPensee, C.R., et al., *ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1,*
435 *Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs.*
436 Endocrinology, 2016. **157**(5): p. 1775-88.
437 40. Cheng, Y., R.E. Kerppola, and T.K. Kerppola, *ATR-101 disrupts mitochondrial functions in*
438 *adrenocortical carcinoma cells and in vivo.* Endocr Relat Cancer, 2016. **23**(4): p. 1-19.
439 41. Beuschlein, F., et al., *Major prognostic role of Ki67 in localized adrenocortical carcinoma after*
440 *complete resection.* J Clin Endocrinol Metab, 2015. **100**(3): p. 841-9.
441 42. Luton, J.P., et al., *Clinical features of adrenocortical carcinoma, prognostic factors, and the*
442 *effect of mitotane therapy.* N Engl J Med, 1990. **322**(17): p. 1195-201.
443 43. Fassnacht, M., et al., *Adrenocortical carcinoma: a clinician's update.* Nat Rev Endocrinol,
444 2011. **7**(6): p. 323-35.
445 44. Scollo, C., et al., *Prognostic Factors for Adrenocortical Carcinoma Outcomes.* Front Endocrinol
446 (Lausanne), 2016. **7**: p. 99.

447 45. Lippert, J., et al., *Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy*
448 *Toward Improved Personalized Prognostication.* J Clin Endocrinol Metab, 2018. **103**(12): p.
449 4511-4523.
450 46. Zhang, F., et al., *Prognostic Role of Ki-67 in Adrenocortical Carcinoma After Primary*
451 *Resection: A Retrospective Mono-Institutional Study.* Adv Ther, 2019. **36**(10): p. 2756-2768.
452 47. Libe, R., *Clinical and molecular prognostic factors in adrenocortical carcinoma.* Minerva
453 Endocrinol, 2019. **44**(1): p. 58-69.
454 48. Libe, R., et al., *Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European*
455 *Network for the Study of Adrenal Tumor (ENSAT) study.* Ann Oncol, 2015. **26**(10): p. 2119-25.

456

457

458

459 **Table 1: Patient characteristics.**

	adjuvant
Patients n	158
Age in years: median (range)	54.2 (17-83)
Sex - n (%)	
female	97 (61)
male	61 (39)
Tumor stage - n (%)	
I	10 (6.5)
II	88 (56)
III	52 (33)
IV	7 (4.5)
R status (n=156)	
0	121 (77.6)
X	30 (19.2)
1	5 (3.2)
Ki67-Index (n=144) - n (%)	
<10%	30 (21)
≥10%	114 (79)
Weiss score (n=142): median (range)	6 (1-9)
Endocrine activity (n=143) - n (%)	
hormone secretion	96 (67)
no over-secretion	47 (33)
Months to mitotane start (median (IQR))	1 (2)
Mitotane plasma concentration at 3 months (median ±SD) (n=132)	9.05 ±5.9
Mitotane plasma concentration at 6 months (median ±SD) (n=125)	13 ±5.7

	advanced disease
Patients n	72
Age in years: median (range)	51 (16-80)
Sex n (%)	
female	42 (58)
male	30 (42)
Tumor stage- n (%)	
I	2 (2.8)
II	19 (26.4)
III	11 (15.3)
IV	40 (55.6)
R status (n=68)	
0	28 (41)
X	15 (22)
1	13 (19)
2	12 (18)
Ki67-Index (n=66) - n (%)	
<10%	18 (27.3)
≥10%	48 (66.4)
Weiss score (n=55): median (range)	6 (1-9)
Endocrine activity (n=62) - n (%)	
hormone secretion	45 (72.6)
no over-secretion	17 (27.4)
Months to mitotane start (median (IQR))	0 (2)
Mitotane level at 3 months (median ±SD) (n=61)	10±6.3
Mitotane level at 6 months (median ±SD) (n=51)	12.5±7

Table 2: Impact of SOAT1 expression and known prognostic parameters on RFS and DSS in the adjuvant (R0 or RX) cohort.

RFS	univariate analysis			multivariate analysis		
variables	HR	95% CI	*p*	HR	95% CI	*p*
Sex						
female (n=91)						
male (n=56)	1.13	0.72-1.76	0.60	1.30	0.77-2.19	0.33
Age						
<50 (n=90)						
≥50 (n=58)	0.78	0.49-1.23	0.29	0.72	0.40-1.29	0.27

Hormone over-secretion						
Yes (n=90)						
No (n=43)	1.39	0.84-2.32	0.20	1.55	0.86-2.77	0.14
Tumor stage						
I+ II (n=90)						
III + IV (n=56)	1.51	0.97-2.34	0.07	1.54	0.90-2.62	0.11
Ki67						
<10 (n=28)						
≥10 (n=107)	3.810	1.64-8.84	0.002*	2.86	1.18-6.96	0.02
Mitotane levels 3 months (median:9.1 mg/l) n=122						
<9.1						
≥9.1	1.50	0.92-2.44	0.11	-	-	-
Mitotane levels 6 months (median:13 mg/l) n=116						
<13						
≥13	1.02	0.62 - 1.67	0.95	-	-	-
SOAT1						
H-Score low: <2 (n=89)						
H-Score high: ≥2 (n=59)	1.42	0.91-2.21	0.12	1.07	0.61-1.85	0.82

DSS	univariate analysis			multivariate analysis		
variables	HR	95% CI	*p*	HR	95% CI	*p*
Sex						
female (n=81)						
male (n=53)	1.19	0.462-2.28	0.61	1.65	0.74-3.67	0.22
Age						
<50 (n=80)						
≥50 (n=55)	0.64	0.32-1.29	0.21	0.60	0.24-1.55	0.29
Hormone over-secretion						
Yes (n=85)						
No (n=36)	1.52	0.68-3.40	0.31	1.48	0.58-3.79	0.42
Tumor stage						
I + II (n=85)						
III + IV (n=48)	1.43	0.74-2.76	0.28	1.23	0.54-2.78	0.63
Ki67						
<10 (n=24)						
≥10 (n=99)	4.91	1.17-20.67	0.03*	3.60	0.80-16.24	0.10
Mitotane levels 3						

months (median:9.1 mg/l) n=112						
<9.1		0.76 –				
≥9.1	1.52	3.06	0.24	-	-	-
Mitotane levels 6 months (median:13 mg/l) n=103						
< 13						
≥13	0.74	0.34-1.60	0.44	-	-	-
SOAT1						
H-Score low: <2 (n=81)						
H-Score high: ≥2 (n=54)	1.49	0.77-2.86	0.24	1.30	0.58-2.93	0.53

Table 3: Impact of SOAT1 expression and known prognostic parameters on PFS and DSS in the cohort with advanced disease. preM-TTP**:** pre mitotane time to progression

PFS	univariate analysis			multivariate analysis		
variables	HR	95% CI	*p*	HR	95% CI	*p*
Sex						
female (n=40)						
male (n=27)	0.75	0.44-1.27	0.28	0.81	0.43-1.53	0.51
Age						
<50 (n=29)						
≥50 (n=38)	0.84	0.50-1.42	0.52	0.73	0.36-1.50	0.40
Hormone over-secretion						
Yes (n=43)						
No (n=14)	1.46	0.77-2.78	0.25	1.98	0.97-4.03	0.06-
preM-TTP						
<365 days						
≥365 days	0.37	0.18-0.72	0.004*	0.49	0.21-1.11	0.09
Ki67						
<10 (n=17)						
≥10 (n=45)	1.19	0.66-2.14	0.55	0.92	0.46-1.83	0.81
Mitotane levels 3 months (median:10 mg/l) n=58						
<10						
≥10	0.70	0.40-1.22	0.21	-	-	-
Mitotane levels 6 months (median:12.5 mg/l) n=48						

<12.5						
≥12.5	0.61	0.33-1.14	0.12	-	-	-
SOAT1						
H-Score low: <2 (n=37)						
H-Score high: ≥2 (n=30)	1.11	0.68-1.86	0.68	1.34	0.63-2.84	0.45

DSS	univariate analysis			multivariate analysis		
variables	HR	95% CI	*p*	HR	95% CI	*p*
Sex						
female (n=36)						
male (n=27)	0.48	0.26-0.92	0.026*	0.92	0.40-2.11	0.83
Age						
<50 (n=27)						
≥50 (n=36)	0.82	0.46-1.48	0.52	1.39	0.63-3.04	0.42
Hormone over-secretion						
Yes (n=40)						
No (n=13)	1.04	0.52-2.07	0.92	1.20	0.52-2.80	0.67
Ki67						
<10 (n=14)						
≥10 (n=45)	2.47	1.14-5.32	0.021*	1.83	0.73-4.60	0.20
preM-TTP						
<365 days		0.014-				
>365 days	0.60	0.257	<0.001*	0.10	0.02-0.49	0.004*
Mitotane levels 3 months (median:10 mg/l) n=54						
<10		0.56-				
≥10	1.05	1.98	0.88	-	-	-
Mitotane levels 6 months (median:12.5 mg/l) n=45						
<12.5						
≥12.5	0.62	0.30-1.27	0.19	-	-	-
SOAT1						
H-Score low: <2 (n=35)						
H-Score high: ≥2 (n=28)	0.81	0.44-1.46	0.48	0.72	0.31-1.70	0.45

465 **Figure legends**

466 **Figure 1: SOAT1 immunohistochemistry staining of full ACC FFPE sections.** First
467 column shows an overview of SOAT1 staining intensities within the same tumors (scale bars:

468 3mm). Second column shows 3x magnification of the representative slide in first column
469 (scale bars: 700µm) and third column shows 20x magnification of the slide shown in column
470 A (scale bars: 200µm) (A-C: SOAT1 H-score 3, inhomogeneous staining; D-F: SOAT1 H-
471 Score 3, inhomogeneous staining; G-I: SOAT1 H-score 2, homogeneous staining, J-L:
472 SOAT1 H-score 0, homogenous staining).

473 **Figure 2: Kaplan-Meier plots of SOAT1 low and high expressing ACC. (A)** Recurrence-
474 /progression-free survival and **(B)** disease-specific survival of all ACC patients. **(C)**
475 Recurrence-free survival **(D) and** disease-specific survival of ACC patients in the adjuvant
476 group. **(E)** progression-free survival **(F)** and disease-specific survival of ACC patients with
477 advanced disease.

478 **Figure 3: SOAT1 expression and treatment response.** No significant differences
479 regarding mitotane response between SOAT1 high and SOAT1 low expressing tumors were
480 observed in the adjuvant arm **(A)**, nor in advanced stages **(B)**.

481 **Figure 4: Correlation of SOAT1 expression and mitotane plasma concentrations. (A)** In
482 both arms, high SOAT1 expression was not correlated with higher mitotane plasma levels.
483 Patients with high SOAT1 expression are not more likely to reach mitotane plasma levels
484 above 14 mg/l not in the adjuvant setting **(B)**, nor in patients with advanced disease **(C)**.
485 When only patients reaching the mitotane target level of 14 mg/l were analysed, high SOAT1
486 expression was significantly correlated with higher rates of recurrences after three months
487 **(D)** which did not retain significance after six months **(E).**